Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
Efficacy and Safety Assessment of NIlotinib in Chronic Myeloid Leukemia (CML) Patients with Suboptimal Response on Imatinib Therapy (NISRI)	KAIMRC	Ongoing	NILOTINIB	4	RC12/052/R	King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam)
Tracking Biologics Along the Silk Road	Janssen-Cilag International NV	Ongoing	Infliximab / Golimumab / Ustekinumab	4	C0168ARA40	King Khalid University Hospital (Riyadh)
A study of the factors predicting radiation exposure to contacts of Saudi patients treated with radioactive iodine (I 131): A preliminary study for patients’ criteria selection for possible high dose I131 therapy on out-patient basis in the future	King Abdulaziz City for Science and Technology (KACST)	Completed	131 Iodine	4	(version#1) dated 10-Apr-14	King Abdullah Medical City (Makkah)
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers, An International, Multicenter, Double Blind, Randomized Placebo Controlled Phase 3 trial (ICR-02/ASCOLT)	King Fahad Medical City	Ongoing	Aspirin	3	ICR-02/ASCOLT	King Fahad Medical City (Riyadh)
Prospective, multicentre, international Registry of male and female patients newly diagnosed with Atrial Fibrillation and treated with Rivaroxaban	Thrombosis Research Institute	Ongoing	Rivaroxaban	4	TRI08890	Armed Forces Hospital (Southern Region)
Middle East Observational Study in Metastatic Soft Tissue Sarcoma: An epidemiological study on the treatment patterns	Novartis	Ongoing	N/A	4	VEG201319	King Faisal Specialist Hospital and Research Center (Riyadh)
XALIA LEA- Xarelto® for Long-term and Initial Anticoagulation in VenousThromboembolism (VTE) in Latin America,EMEA and Asia	Bayer	Ongoing	Rivaroxaban	4	17237	King Fahad Medical City (Riyadh), King Fahad Hospital (Madinah), King Faisal Hospital (Taif), Hira Hospital (Makkah)
(FLASH study)A 12-week treatment, multi-center, randomized, doubleblind,double-dummy, parallel group study to assess the efficacy and safety of switching fromsalmeterol/fluticasone to QVA149 (indacaterolmaleate/glycopyrronium bromide) in symptomatic COPD patients	Novartis	Ongoing	Ultibro breezhaler	4	A3405 V01	King Fahad Medical City (Riyadh), King Fahad University Hospital (Al-Khobar), King Abdulaziz Medical City NG (Jeddah)
Early Goal Directed Sedation vs. Standard Care Sedation	The Australian and New Zealand Intensive Care Research Centre, Monash University, Australia	Ongoing	Dexmedetomidine	4	YS/003	King Saud Medical City (Riyadh)
Prospective Multicentre Observational Registry Of Treatments And Outcomes In Patients With Chronic	Astellas Pharma International	Ongoing	N/A	4	ONC-MA1002	Aseer Central Hospital